PLA2G6-Associated Neurodegeneration (PLAN)

PLA2G6-Associated Neurodegeneration (PLAN)

Introduction

Pla2G6 Associated Neurodegeneration (Plan) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

PLA2G6-associated neurodegeneration (PLAN) is a group of rare autosomal recessive neurodegenerative disorders caused by mutations in the PLA2G6 gene (Phospholipase A2, Group VI).^[1] This condition encompasses a spectrum of phenotypes ranging from severe infantile-onset disease to adult-onset dystonia-parkinsonism.^[2] [@female]

Overview

PLA2G6 encodes calcium-independent phospholipase A2 (iPLA2-VI), an enzyme crucial for phospholipid metabolism and mitochondrial function in [neurons](/entities/neurons).^[3] Loss of iPLA2-VI activity leads to impaired membrane remodeling, mitochondrial dysfunction, and progressive neuronal death. [@claval]

The three main phenotypes within the PLAN spectrum include: [@comprehensive]

Infantile Neuroaxonal Dystrophy (INAD) - Classic early-onset form

Atypical Neuroaxonal Dystrophy (aNAD) - Intermediate form with later onset

Adult-Onset Dystonia-Parkinsonism (ADP) - Adult-onset form

Genetics

PLA2G6 Gene

| Property | Value | [@clinicoradiologic]
|----------|-------| [^6]
| Gene Symbol | PLA2G6 | [^7]
| Chromosomal Location | 22q12.1-q13.2 | [^8]
| Protein | Calcium-independent phospholipase A2 (iPLA2-VI) |
| Inheritance | Autosomal Recessive |
| OMIM | 603604 |

...

PLA2G6-Associated Neurodegeneration (PLAN)

Introduction

Pla2G6 Associated Neurodegeneration (Plan) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

PLA2G6-associated neurodegeneration (PLAN) is a group of rare autosomal recessive neurodegenerative disorders caused by mutations in the PLA2G6 gene (Phospholipase A2, Group VI).^[1] This condition encompasses a spectrum of phenotypes ranging from severe infantile-onset disease to adult-onset dystonia-parkinsonism.^[2] [@female]

Overview

PLA2G6 encodes calcium-independent phospholipase A2 (iPLA2-VI), an enzyme crucial for phospholipid metabolism and mitochondrial function in [neurons](/entities/neurons).^[3] Loss of iPLA2-VI activity leads to impaired membrane remodeling, mitochondrial dysfunction, and progressive neuronal death. [@claval]

The three main phenotypes within the PLAN spectrum include: [@comprehensive]

Infantile Neuroaxonal Dystrophy (INAD) - Classic early-onset form

Atypical Neuroaxonal Dystrophy (aNAD) - Intermediate form with later onset

Adult-Onset Dystonia-Parkinsonism (ADP) - Adult-onset form

Genetics

PLA2G6 Gene

| Property | Value | [@clinicoradiologic]
|----------|-------| [^6]
| Gene Symbol | PLA2G6 | [^7]
| Chromosomal Location | 22q12.1-q13.2 | [^8]
| Protein | Calcium-independent phospholipase A2 (iPLA2-VI) |
| Inheritance | Autosomal Recessive |
| OMIM | 603604 |

Over 100 pathogenic variants have been identified in PLA2G6, including missense, nonsense, splice-site, and frameshift mutations.^[1] Common founder mutations have been described in various populations.^[8]

Pathogenic Mechanism

The iPLA2-VI enzyme catalyzes the hydrolysis of the sn-2 position of phospholipids, releasing fatty acids including arachidonic acid, a precursor for pro-inflammatory eicosanoids.^[3] Loss of enzymatic function leads to:

• Accumulation of phospholipid peroxidation products
• Mitochondrial dysfunction and energy failure^[3]
• Impaired membrane trafficking
• Oxidative stress in neurons
• Progressive axonal degeneration

Clinical Features

Infantile Neuroaxonal Dystrophy (INAD)

INAD presents in the first 2 years of life with:^[4]

• Motor regression - Loss of previously acquired motor skills
• Hypotonia - Decreased muscle tone
• Ataxia - Coordination difficulties
• Spasticity - Muscle stiffness
• Nystagmus - Involuntary eye movements
• Visual impairment - Often due to optic atrophy
• Seizures - Present in ~50% of cases
• Cognitive decline - Progressive intellectual deterioration

Typical disease course shows rapid progression with loss of ambulation within 2-3 years of onset. Most individuals do not survive beyond adolescence.

Atypical Neuroaxonal Dystrophy (aNAD)

aNAD presents between ages 2-10 years with:^[2]

• Gait instability and clumsiness
• Speech delay or regression
• Behavioral changes including irritability
• symptoms that progress Mild motor more slowly than INAD
• Seizures in some cases

Disease progression is slower than INAD, with survival into adulthood possible.

Adult-Onset Dystonia-Parkinsonism (ADP)

ADP presents in adolescence or adulthood with:^[5]

• Dystonia - Involuntary muscle contractions, often affecting neck and limbs
• Parkinsonism - Tremor, bradykinesia, rigidity
• Cognitive impairment - Variable, often mild
• Psychiatric symptoms - Depression, anxiety

This form has a more indolent course compared to the childhood-onset forms.

Diagnosis

Clinical Diagnosis

Diagnostic criteria include:

Progressive neurodegenerative course

Characteristic MRI findings (see below)

Family history consistent with autosomal recessive inheritance

Exclusion of other similar conditions

Neuroimaging

MRI findings in PLAN:^[6]

• Cerebellar atrophy (especially vermis)
• Iron accumulation in the globus pallidus (T2 hypointensity)
• White matter abnormalities
• Thin or absent corpus callosum in severe cases
• Optic nerve atrophy on orbital MRI

Genetic Testing

• Sequencing of the entire PLA2G6 coding region
• Deletion/duplication analysis to detect copy number variants
• Prenatal testing available for families with known mutations

Biomarkers

Elevated [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) in cerebrospinal fluid has been reported as a biomarker of disease progression.

Treatment

Symptomatic Treatment

There is currently no disease-modifying therapy for PLAN. Treatment is supportive and symptomatic:

• Antiepileptic drugs for seizure control
• Muscle relaxants for spasticity (baclofen, benzodiazepines)
• Dopaminergic agents for parkinsonism (may provide partial benefit in ADP)^[5]
• Physical therapy to maintain mobility
• Occupational therapy for daily activities
• Speech therapy for communication difficulties
• Assistive devices as needed (wheelchairs, communication aids)

Experimental Approaches

Research directions include:^[7]

• Gene therapy - AAV-mediated PLA2G6 delivery
• Small molecule iPLA2 inhibitors - To reduce toxic lipid accumulation
• Antioxidant therapy - To combat oxidative stress
• Mitochondrial protectants
• Neurotrophic factors - To support neuron survival

Prognosis

| Phenotype | Typical Course | Life Expectancy |
|-----------|----------------|-----------------|
| INAD | Rapid progression | Death in childhood/adolescence |
| aNAD | Intermediate progression | Survival to adulthood |
| ADP | Slow progression | Normal or near-normal lifespan |

Epidemiology

• Estimated prevalence: 1 in 1,000,000 to 1 in 2,000,000
• Higher incidence in populations with founder mutations
• Equal male-to-female ratio
• No ethnic predilection for most mutations

Animal Models

Mouse models with PLA2G6 knockout show:

• Age-dependent neurodegeneration
• Motor deficits
• Iron accumulation
• Mitochondrial dysfunction

These models are being used to test experimental therapeutics.^[7]

Research Directions

Current research focuses on:

Understanding genotype-phenotype correlations

Developing biomarkers for clinical trials

Gene therapy approaches using AAV vectors^[7]

Small molecule modulators of iPLA2 activity

Repurposing existing drugs for symptomatic benefit

See Also

• [Neuroaxonal Dystrophy](/diseases/infantile-neuroaxonal-dystrophy)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dystonia](/diseases/dystonia)
• [Iron Accumulation Neurodegeneration](/mechanisms/iron-accumulation-neurodegeneration)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-ad)

External Links

• [OMIM: PLA2G6](https://www.omim.org/entry/603604)
• [GeneReviews: PLA2G6-Associated Neurodegeneration](https://www.ncbi.nlm.nih.gov/books/NBK1975/)
• [NIH Genetic and Rare Diseases Information Center: PLAN](https://rarediseases.info.nih.gov/diseases/12483/pla2g6-associated-neurodegeneration)
• [MedlinePlus: Neuroaxonal Dystrophy](https://medlineplus.gov/genetics/condition/neuroaxonal-dystrophy/)

Background

The study of Pla2G6 Associated Neurodegeneration (Plan) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Prospective 5-year natural history study of infantile PLA2G6-associated neurodegeneration.](https://pubmed.ncbi.nlm.nih.gov/40785249/) (2026 Apr) - Developmental medicine and child neurology
• A female case of phospholipase A2 group VI-associated neurodegeneration with childhood onset and long-term follow-up until 49 years of age.](https://pubmed.ncbi.nlm.nih.gov/41813186/) (2026 Mar 11) - Rinsho shinkeigaku = Clinical neurology
• [Claval Hypertrophy with Persistent Diffusion Restriction in PLA2G6-Associated Neurodegeneration.](https://pubmed.ncbi.nlm.nih.gov/41804185/) (2026 Mar 9) - Movement disorders clinical practice
• [A Comprehensive Overview of the Clinical, Electrophysiological, and Neuroimaging Features of BPAN: Insights From a New Case Series.](https://pubmed.ncbi.nlm.nih.gov/41097835/) (2026 Mar) - Annals of clinical and translational neurology
• [Clinicoradiologic Features and Genetic Findings of Infantile Neuroaxonal Dystrophy.](https://pubmed.ncbi.nlm.nih.gov/40754933/) (2026 Mar) - Journal of child neurology

References

[Unknown, Prospective 5-year natural history study of infantile PLA2G6-associated neurodegeneration (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40785249/)

PMID: 41813186(https://pubmed.ncbi.nlm.nih.gov/41813186/)

[Unknown, Claval Hypertrophy with Persistent Diffusion Restriction in PLA2G6-Associated Neurodegeneration (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41804185/)

[Unknown, A Comprehensive Overview of the Clinical, Electrophysiological, and Neuroimaging Features of BPAN: Insights From a New Case Series (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41097835/)

[Unknown, Clinicoradiologic Features and Genetic Findings of Infantile Neuroaxonal Dystrophy (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40754933/)